GSK Korea’s immno-oncology latecomer drug ‘Jemperli (dostarlimab)’ has passed its first step to reimbursement in Korea.

On the other hand, Koselugo (selumetinib), AstraZeneca’s new drug for pediatric patients with neurofibromatosis type 1 (NF1), received a redicussion decision, warning of a bumpy journey ahead.

The Health Insurance Review and Assessment Service held its 8th 2023 Drug Reimbursement Evaluation Committee meeting and deliberated on the adequacy of reimbursement of 6 new drugs and made the decisions above.

New drugs that were deliberated and deemed eligible for reimbursement include Jemperli and Ono Pharma Korea’s BRAF inhibitor for colorectal cancer, ‘B